Loading...
XSHE300006
Market cap479mUSD
Jan 10, Last price  
3.33CNY
1D
-4.58%
1Q
-10.96%
Jan 2017
-60.59%
IPO
-25.59%
Name

Chongqing Lummy Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300006 chart
P/E
—
P/S
3.93
EPS
—
Div Yield, %
0.34%
Shrs. gr., 5y
5.28%
Rev. gr., 5y
-10.53%
Revenues
896m
+1.24%
96,474,746166,055,339265,220,201333,544,459377,648,123534,094,504631,461,353759,117,978911,801,664963,975,193990,216,3731,282,070,9921,562,367,0311,859,010,7591,583,529,9131,225,224,188884,586,776895,592,665
Net income
-9m
8,543,22124,493,48732,886,66840,467,78843,868,64373,090,49753,712,13460,808,5599,278,65420,612,3896,981,14555,561,45598,003,3160000-8,927,328
CFO
82m
+42.70%
7,765,95521,681,17317,247,59737,348,38937,657,61511,850,80618,182,36374,695,39600125,658,76061,387,916225,885,520231,298,140224,539,200108,281,30257,133,94981,531,392
Dividend
Jul 03, 20200.05 CNY/sh
Earnings
Apr 11, 2025

Profile

Chongqing Lummy Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products in China. The company provides tumor, antibacterial, antiviral, and antifungal, as well as liver disease auxiliary, endocrinology system, and Chinese patent drugs; digestive system, immune system, blood system, cardiovascular system, and nervous system drugs; electrolyte and acid-base products; balance and nutritional products; and base large infusion products, American ginseng systems, and active pharmaceutical ingredients. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is based in Chongqing, China.
URL
http://www.cqlummy.com
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
895,593
1.24%
884,587
-27.80%
Cost of revenue
839,982
885,011
Unusual Expense (Income)
NOPBT
55,611
(424)
NOPBT Margin
6.21%
Operating Taxes
13,612
1,038
Tax Rate
24.48%
NOPAT
41,999
(1,462)
Net income
(8,927)
 
Dividends
(11,804)
Dividend yield
0.30%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
113,500
209,700
Long-term debt
131,554
162,131
Deferred revenue
6,392
9,043
Other long-term liabilities
58,153
1
Net debt
(1,107,091)
(1,005,949)
Cash flow
Cash from operating activities
81,531
57,134
CAPEX
(59,319)
Cash from investing activities
(119,518)
13,817
Cash from financing activities
(81,243)
166,066
FCF
139,627
331,184
Balance
Cash
836,437
846,286
Long term investments
515,708
531,493
Excess cash
1,307,365
1,333,550
Stockholders' equity
628,495
1,170,456
Invested Capital
1,794,351
1,363,236
ROIC
2.66%
ROCE
2.28%
EV
Common stock shares outstanding
1,050,274
1,055,911
Price
3.72
-2.36%
3.81
-44.13%
Market cap
3,907,019
-2.88%
4,023,022
-40.73%
EV
2,841,442
3,077,591
EBITDA
131,028
75,984
EV/EBITDA
21.69
40.50
Interest
12,594
20,345
Interest/NOPBT
22.65%